MediWound gets $3.3M more from U.S. government for NexoBrid program

Go back to MediWound gets $3.3M more from U.S. government for NexoBrid program

MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®

September 22, 2026 7:00 AM EDT

MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®

Award raises the total program budget to $21.8 million and supports development through Investigational New Drug (IND) submission for battlefield burn care

YAVNE, Israel, September 22, 2026 MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the U.S. Department of War (DoW) has awarded the Company an additional $3.3 million in non-dilutive funding to advance the development of a room-temperature-stable... More